Advertisement

Topics

Karuna Pharmaceuticals, Inc. Company Profile

12:47 EDT 22nd March 2019 | BioPortfolio

Karuna is a clinical-stage drug development company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease, as well as pain. Karuna’s lead product candidate, KarXT (Karuna-Xanomeline-Trospium), is being evaluated in a Phase 2 study in people with schizophrenia, with top-line results anticipated at the end of 2019. Karuna, which was founded by PureTech Health (LSE: PRTC), has a worldwide exclusive license for xanomeline and has an intellectual property portfolio more broadly covering selective muscarinic targeting enabled by the KarXT approach. For more information, visit www.karunapharma.com.


News Articles [410 Associated News Articles listed on BioPortfolio]

Karuna doses first patient in study of KarXT for schizophrenia

Karuna Pharmaceuticals has dosed the first patient in a Phase II study to examine the efficacy and safety of Karuna-Xanomeline-Trospium...Read More... The post Karuna doses first patient in study of K...

Karuna raises $68m to develop neurology drug KarXT

Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia. Formerly known as ...

Karuna closes $42mm Series A round to advance KarXT schizophrenia candidate

CNS-focused Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) raised $42mm in a Series A round; $22mm of that amount includes the issuance of shares upon conve...

PureTech affiliate Karuna advances schizophrenia candidate

Karuna Pharmaceuticals, an affiliate of UK biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.

PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate

Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia...   

Karuna brings in $68mm through its Series B round

Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) completed a $68mm Series B round; $5mm of that amount includes the issuance of shares upon conversion of debt...

Karuna Snags $68 Million to Support Schizophrenia Treatment Development

The latest financing round will boost the study of KarXT, Karuna’s lead product candidate, which is currently in Phase II development as a potential treatment for acute psychosis in patients with sc...

Karuna Appoints Jeff Jonas, M.D., to Board of Directors

Industry leader brings extensive experience in building and leading clinical development programs for central nervous system disorders Karuna Pharmaceuticals, Inc. (“...

Drugs and Medications [0 Results]

None

PubMed Articles [147 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Insight into the distribution of pharmaceuticals in soil-water-plant systems.

Pharmaceuticals in agricultural soils originating from irrigation with treated wastewater and land-applied biosolids can enter field crops. However, little is known about the role of pore water in pla...

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.

National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visi...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Clinical Trials [231 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1355 Associated Companies listed on BioPortfolio]

Karuna Pharmaceuticals, Inc.

Karuna is a clinical-stage drug development company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous syste...

Karuna Pharmaceuticals

Karuna Therapeutics, Inc.

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

More Information about "Karuna Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Karuna Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Karuna Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Karuna Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Karuna Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Karuna Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record